Vaccine, Japanese encephalitis


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intramuscular
Active immunisation against encephalitis due to Japanese encephalitis virus
Adult: As adsorbed, inactivated virus vaccine: Primary immunisation: 0.5 mL at 0 and 28 days. Alternatively, an accelerated schedule consisting of 0.5 mL at 0 and 7 days may be given when there is insufficient time for the standard course. Primary course should be completed at least 1 week before potential exposure. Booster dose: Given 12-24 months (12 months for those at continued risk) after the primary course.
Child: Primary immunisation: 2 months to <3 years 0.25 mL at 0 and 28 days; ≥3-17 years Same as adult dose. Booster dose: Given 12-24 months (12 months for those at continued risk) after the primary course.

Subcutaneous
Active immunisation against encephalitis due to Japanese encephalitis virus
Adult: As live, attenuated virus vaccine: Primary immunisation: 0.5 mL as single dose. Booster dose: May be given 5 years after the primary dose, in patients at continued risk.
Child: 9 months to 17 years Primary immunisation: 0.5 mL as single dose. Booster dose: Given 12-24 months after the primary dose, in patients at continued risk.
Chống chỉ định
Hypersensitivity. Live, attenuated virus vaccine: Congenital or acquired immunodeficiency (e.g. HIV infection). Pregnancy and lactation (live, attenuated virus vaccine).
Thận trọng
Patients with bleeding disorders (e.g. thrombocytopenia, haemophilia), altered immunocompetence, personal or family history of febrile convulsions. Postpone vaccination in case of acute severe febrile or acute illness. Children. Pregnancy and lactation (adsorbed, inactivated virus vaccine).
Phản ứng phụ
Significant: Syncope.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Fatigue, fever, malaise, irritability; injection site reaction (e.g. tenderness, pain, erythema, swelling, bruising).
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, chills.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Cough, dyspnoea, nasal congestion, pharyngolaryngeal pain, wheezing.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Anaphylaxis.
MonitoringParameters
Monitor for anaphylaxis and syncope 15 minutes after administration.
Tương tác
Increased risk of bleeding with anticoagulants (IM). Decreased immune response when given with immunosuppressants (e.g. high-dose corticosteroids).
Tác dụng
Description: Japanese encephalitis vaccine triggers the immune system to produce neutralising antibodies against Japanese encephalitis virus which correlate with protection and survival.
Onset: 10 days after 1st dose and 28 days after 2nd dose.
Duration: 12-36 months after initiation of the primary course.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed in accordance with local requirements.
Phân loại ATC
J07BA03 - encephalitis, Japanese, live attenuated ; Belongs to the class of encephalitis viral vaccines.
J07BA02 - encephalitis, Japanese, inactivated, whole virus ; Belongs to the class of encephalitis viral vaccines.
References
Anon. Japanese Encephalitis Virus Vaccine (Inactivated). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2018.

Buckingham R (ed). Japanese Encephalitis Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2018.

IXIARO Inactivated, Adsorbed Injection, Suspension (Valneva Scotland Ltd.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2018.

Joint Formulary Committee. Japanese Encephalitis Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vaccine, Japanese encephalitis từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Japanese Encephalitis Vaccine-GCC
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in